Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Étude de Patritumab Deruxecan plus pembrolizumab avec d'autres agents anticancéreux chez les participants atteints d'un cancer du sein triple négatif ou hormonal à haut stade à haut risque (MK-1022-010, Herthena-Breast-03)

11 novembre 2026 mis à jour par: Merck Sharp & Dohme LLC

Une étude de phase 2 randomisée ouverte pour évaluer la sécurité et l'efficacité de Patritumab Deruxecan plus pembrolizumab administré avant ou après la carboplatine / paclitaxel plus pembrolizumab par rapport au pembrolizumab en combinaison avec une chimiothérapie suivie d'une intervention chirurgicale et d'un pembrolizum de haut risque à haut risque Récepteur négatif ou hormonal-bas positif / humain Facteur de croissance épidermique Récepteur-2 Cancer du sein négatif (Herthhena-Breast03)

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

  • About the safety of the study treatments and if people tolerate them
  • If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

372

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

      • Seoul, Corée du Sud, 03080
        • Recrutement
        • Seoul National University Hospital ( Site 2400)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82220720850
      • Seoul, Corée du Sud, 05505
        • Recrutement
        • Asan Medical Center ( Site 2401)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82230103217
      • Seoul, Corée du Sud, 03722
        • Recrutement
        • Severance Hospital, Yonsei University Health System ( Site 2402)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +82222288135
      • Córdoba, Espagne, 14004
        • Recrutement
        • Hospital Universitario Reina Sofia ( Site 1702)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34 957012408
    • Catalonia
      • Badalona, Catalonia, Espagne, 08916
        • Recrutement
        • Institut Català d'Oncologia (ICO) - Badalona ( Site 1700)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34934978925
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Espagne, 28027
        • Recrutement
        • Clinica Universidad de Navarra ( Site 1703)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +34913531920
      • Taichung, Taïwan, 407
        • Recrutement
        • Taichung Veterans General Hospital ( Site 2502)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +886423592525
      • Tainan, Taïwan, 704
        • Recrutement
        • National Cheng Kung University Hospital ( Site 2503)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: +88662353535
      • Taipei, Taïwan, 112
        • Recrutement
        • Koo Foundation Sun Yat-Sen Cancer Center ( Site 2501)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 886228970011x1686
    • California
      • Santa Monica, California, États-Unis, 90404
        • Recrutement
        • UCLA Hematology/Oncology - Parkside ( Site 0021)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 424-402-9520
    • Illinois
      • Skokie, Illinois, États-Unis, 60077
        • Recrutement
        • Orchard Healthcare Research Inc. ( Site 0006)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 847-568-9932
    • Montana
      • Billings, Montana, États-Unis, 59102
        • Recrutement
        • Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana ( Site 0003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 406-238-6685
    • Oregon
      • Happy Valley, Oregon, États-Unis, 97015
        • Recrutement
        • Northwest Cancer Specialists, P.C. ( Site 8003)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 360-944-9889
    • Tennessee
      • Nashville, Tennessee, États-Unis, 37203
        • Recrutement
        • SCRI Oncology Partners ( Site 7000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 844-482-4812
    • Texas
      • Dallas, Texas, États-Unis, 75246
        • Recrutement
        • Texas Oncology - DFW ( Site 8000)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 214-370-1067
      • Houston, Texas, États-Unis, 77030
        • Recrutement
        • Houston Methodist Hospital ( Site 0022)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 713-441-9948
    • Virginia
      • Norfolk, Virginia, États-Unis, 23502
        • Recrutement
        • Virginia Oncology Associates (VOA) ( Site 8001)
        • Contact:
          • Study Coordinator
          • Numéro de téléphone: 844-482-4812

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

The main inclusion criteria include but are not limited to the following:

  • Has locally advanced, non-metastatic (M0), breast cancer, defined as any of the following combined primary tumor (T) and regional lymph node (N) staging per current American Joint Committee on Cancer (AJCC) criteria: cT1c, N1-N2; cT2, N0-N2; cT3, N0-N2; or cT4a-d, N0-N2
  • Has centrally confirmed diagnosis of breast cancer that is triple-negative or HR-low+/HER2- breast cancer that will be treated according to the triple-negative breast cancer (TNBC) paradigm
  • Participants who are Hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load
  • Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 28 days prior to allocation/randomization
  • Has left ventricular ejection fraction (LVEF) of ≥50% or ≥ lower limit of normal (LLN) as assessed by echocardiogram (ECHO) or multigate acquisition scan (MUGA) scan

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has uncontrolled or significant cardiovascular disease before randomization
  • Has any history of or evidence of any current leptomeningeal carcinomatosis.
  • Has clinically significant corneal disease
  • Has human immunodeficiency virus (HIV) infection with a history of Kaposi sarcoma and/or multicentric Castleman disease
  • Has evidence of ongoing, uncontrolled, systemic bacterial, fungal, or viral infection
  • Has received prior therapy with an anti-programmed death (PD)-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior treatment with an anti-human epidermal growth factor receptor 3 (HER3) antibody and/or antibody-drug conjugate (ADC) that consists of an exatecan derivative that is a topoisomerase I inhibitor (e.g., trastuzumab deruxtecan)
  • Has metastatic (Stage IV) breast cancer or cN3 nodal involvement
  • Has known additional malignancy that is progressing or has required active treatment within the past 5 years
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
  • Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current or suspected ILD
  • Has an active infection requiring systemic therapy
  • Has concurrent active HBV and HCV infection
  • Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Part 1, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 1, participants receive neoadjuvant pembrolizumab 200 mg via intravenous (IV) infusion every 3 weeks (Q3W) plus patritumab deruxtecan via IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg via IV infusion Q3W plus paclitaxel 80 mg/m^2 via IV infusion every week (QW) and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer.

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Autres noms:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • PARAPLATINE®
Expérimental: Part 2, A: Pembrolizimab + patritumab deruxtecan → Pembrolizumab + paclitaxel + carboplatin

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion every Q3W plus patritumab deruxtecan (dose to be determined in part 1) IV infusion Q3W for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks. At 3-6 weeks after last dose of neoadjuvant treatment, participants undergo surgery for breast cancer. After surgery, participants receive adjuvant pembrolizumab 400 mg IV every 6 weeks (Q6W) for ~30 weeks. Additional adjuvant treatment of physician's choice (TPC) may be given to participants with residual disease. TPC options are olaparib 300 mg oral twice daily (BID) for 1 year (participants with germline BRCA mutation [gBRCAm] only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV Q3W or every 2 weeks (Q2W) and cyclophosphamide 600 mg/m^2 IV Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Autres noms:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • PARAPLATINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ADRIAMYCINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Autres noms:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Autres noms:
  • LYNPARZA®
Expérimental: Part 2, B: Pembrolizumab + paclitaxel + carboplatin → Pembrolizumab + patritumab deruxtecan

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus patritumab deruxtecan (dose to be determined in part 1) via IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for ~30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only), capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles or doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W or Q2W and cyclophosphamide 600 mg/m^2 IV infusion Q3W or Q2W for 4 doses.

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • U3-1402
  • HER3-DXd
  • MK-1022

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Autres noms:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • PARAPLATINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ADRIAMYCINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Autres noms:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Autres noms:
  • LYNPARZA®
Comparateur actif: Part 2, C: Pembro + paclitaxel + carboplatin→ Pembro + doxorubicin (or epirubicin) +cyclophosphamide

In Part 2, participants receive neoadjuvant pembrolizumab 200 mg IV infusion Q3W plus paclitaxel 80 mg/m^2 IV infusion QW and carboplatin AUC1.5 mg/ml/min via IV infusion QW for 12 weeks, followed by pembrolizumab 200 mg IV infusion Q3W plus doxorubicin 60mg/m^2 (or epirubicin 90 mg/m^2) IV infusion Q3W and cyclophosphamide 600 mg/m^2 IV infusion Q3W for 12 weeks. At 3 to 6 weeks after last dose of neoadjuvant treatment, participants will undergo surgery for their breast cancer. After surgery, participants will receive adjuvant pembrolizumab 400 mg IV infusion Q6W for approximately 30 weeks. Additional adjuvant TPC may be administered to participants with residual disease. TPC options include olaparib 300 mg oral BID for 1 year (participants with gBRCAm only) or capecitabine 1000-1250 mg/m^2 oral BID days 1-14 and 22-35 Q6W for 4 six-week cycles.

Administered via IV infusion as neoadjuvant treatment in Part 1 and via IV infusion as neoadjuvant and adjuvant treatment in Part 2

Autres noms:
  • MK-3475
  • KEYTRUDA®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • TAXOL®
  • ONXAL®

Administered via IV infusion as neoadjuvant treatment

Autres noms:
  • PARAPLATINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ADRIAMYCINE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • ELLENCE®

Administered via IV infusion as neoadjuvant treatment in Arm C and an option for adjuvant treatment for participants with residual disease in Arms A and B in Part 2

Autres noms:
  • CYTOXAN®

Administered via oral tablets as an option for adjuvant treatment for participants with residual disease in Part 2

Autres noms:
  • XELODA®

Administered via oral tablets as an option for adjuvant treatment for participants with germline BRCA mutations and residual disease in Part 2

Autres noms:
  • LYNPARZA®

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Part 1: Number of Participants Experiencing an Adverse Event (AE)
Délai: Up to ~43 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 1.

Up to ~43 weeks
Part 1: Number of Participants Who Experience One or More Dose-Limiting Toxicities (DLTs)
Délai: Up to 21 days

A DLT is defined by the National Cancer Institute Common Terminology for Adverse Events (NCI CTCAE) Version 5.0, assessed by investigator as drug-related: Grade (gr) 3 or 4 nonhematologic toxicity (with exceptions); gr 3 or gr 4 laboratory values (with exceptions); gr 3 or 4 febrile neutropenia; prolonged delay (>2 weeks) in initiating Cycle 2 (cycle length = 3 weeks) due to intervention-related toxicity; any intervention-related toxicity that causes the participant to discontinue intervention during Cycle 1; interstitial lung disease as per investigator; any other gr ≥3 pulmonary toxicity; or gr 5 toxicity.

Up to 21 days
Part 1: Number of Participants who Discontinued Study Treatment Due to an AE
Délai: Up to ~30 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 1.

Up to ~30 weeks
Part 2: Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0
Délai: Up to ~30 weeks

pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Number of Participants Experiencing an AE
Délai: Up to ~103 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who experience an AE will be presented for Part 2.

Up to ~103 weeks
Part 2: Number of Participants who Discontinued Study Treatment Due to an AE
Délai: Up to ~90 weeks

An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment. The number of participants who discontinued study treatment due to an AE will be presented for Part 2.

Up to ~90 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Part 2: pCR-No Ductal Carcinoma in Situ (DCIS) Rate Using the Definition of ypT0 ypN0
Délai: Up to ~30 weeks

pCR-no DCIS (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy at the time of definitive surgery.

Up to ~30 weeks
Part 2: Event-Free Survival (EFS)
Délai: Up to ~100 months

EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Overall Survival (OS)
Délai: Up to ~100 months

OS is defined as the time from randomization to date of death due to any cause.

Up to ~100 months
Part 2: Distant Progression or Distant Recurrence-Free Survival (DPDRFS)
Délai: Up to ~100 months

DPDRFS is defined as the time from randomization to first distant progression or distant recurrence event as assessed or death due to any cause, whichever occurs first.

Up to ~100 months
Part 2: Residual Cancer Burden (RCB)
Délai: Up to ~30 weeks

RCB is defined as residual disease in either the breast or lymph node at the time of surgery. RCB score provides a continuous measurement of the extent of residual cancer. There are four RCB classes: RCB-0 (RCB score 0), RCB-1 (0< RCB score <1.36), RCB-2 (1.36 <RCB score <3.28), and RCB-3 (RCB score >3.28).

Up to ~30 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Collaborateurs

Les enquêteurs

  • Directeur d'études: Medical Director, Merck Sharp & Dohme LLC

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

20 mars 2025

Achèvement primaire (Estimé)

31 décembre 2029

Achèvement de l'étude (Estimé)

16 mars 2031

Dates d'inscription aux études

Première soumission

21 janvier 2025

Première soumission répondant aux critères de contrôle qualité

21 janvier 2025

Première publication (Réel)

28 janvier 2025

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

12 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

11 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner